Antiretroviral therapy (ART) has been associated with unfavourable lipid profile changes and increased risk of cardiovascular disease (CVD). With a growing population on ART in South Africa, there has been concern about the increase in noncommunicable diseases such as CVD. We determined risk factors associated with increased total cholesterol (TC) in a large cohort on ART and describe the clinical management thereof.
Introduction
Antiretroviral therapy (ART) has led to significant reductions in HIV-related mortality and disease progression, increased life expectancy, and brought about great improvements in quality of life for HIV-infected patients [1] [2] [3] [4] [5] . Concern is growing, however, about emerging evidence of associations between ART and increased risk of cardiovascular disease (CVD). Long-term ART use has been closely linked to CVD risk factors such as hypertension and distortions of metabolic pathways (e.g. hyperlipidaemia, fat redistribution and insulin resistance) [6] [7] [8] [9] [10] [11] [12] .
The impact of ART on lipid profiles varies depending on the ART regimen used [10, 11, 13, 14] , further complicated by the fact that HIV alone has been shown to affect lipid profiles [15] [16] [17] . Briefly, the non-nucleoside reverse transcriptase inhibitors (NNRTIs) efavirenz (EFV) and nevirapine (NVP) as well as the nucleoside reverse transcriptase inhibitors (NRTIs) stavudine (d4T) and zidovudine (ZDV) have all been shown to increase total cholesterol (TC), low-density lipoprotein cholesterol (LDLc), high-density lipoprotein cholesterol (HDL-c) and triglycerides [7, 9, 12, 13, [18] [19] [20] [21] [22] [23] [24] . Similarly, most protease inhibitors (PIs) are also thought to increase TC and LDLc, but have been shown to decrease HDL-c [13] . Tenofovir (TDF) has been associated with more favourable lipid outcomes compared with NNRTIs and PIs, while lamivudine (3TC) has been shown to have little impact [13] .
Now that many countries in sub-Saharan Africa have transitioned to TDF from d4T and ZDV, fewer cases of elevated TC should be observed. As the HIV-infected population ages, however, the overall number of cases of CVD among patients on ART is likely to increase [9, 13, 14] . Monitoring any potential benefits of TDF in maintaining cholesterol is also complicated by potential confounding by age, body mass index (BMI), and indication (i.e. patients may only be put on drugs other than TDF if deemed to be at low risk for elevated TC) as well as potential surveillance bias (TC is monitored less rigorously among patients receiving TDF compared with other drugs, as TDF is perceived to be safer). It is thus important to fully understand the impact of ART and specific drug choices on TC in view of potentially strong confounders and sources of bias. The aim of this analysis was to describe incident elevated TC, as a measure for potential CVD risk, in a large South African population on first-line ART. LDL-c and HDL-c were sparsely recorded in our data and we could not extend the analysis to these variables. The analysis period, covering > 5 years, enabled us to explore the effects of drug choice on TC in a real-world setting.
Methods

Study population
This analysis was conducted among ART-na€ ıve adults initiating a standard first-line ART regimen between April 2010 and April 2014. The patient cohort attended the Themba Lethu Clinic, a large urban HIV clinic at Helen Joseph Hospital in Johannesburg, South Africa [25] . Patients were initiated on ART according to the South African National ART guidelines [26, 27] . Prior to August 2011, patients were eligible for initiation with a CD4 count of ≤ 200 cells/lL or if they presented with a World Health Organization (WHO) stage IV condition. After August 2011, the ART eligibility threshold was raised to a CD4 count of ≤350 cells/lL or WHO stage III/IV condition regardless of CD4 count. The standard first-line regimen during this time consisted of two NRTIs and one NNRTI.
At the study site, patients' demographic characteristics, laboratory tests performed, medications prescribed, and clinical diagnoses were routinely captured using a patient-level electronic data collection system, TherapyEdge-HIV TM (Advanced Biological Laboratories (ABL) S.A., Luxembourg). Laboratory results were electronically downloaded from the National Health Laboratory Service. CD4 count and haemoglobin are measured at ART initiation (defined as up to 90 days prior and 7 days after ART start date). Follow-up clinical monitoring included CD4 count and viral load at 6 and 12 months post-ART initiation and annually thereafter. Guidelines released in 2010 and 2013 called for fasting cholesterol to be measured at 3 months post-ART only if patients were initiated on lopinavir, but at our study site TC was routinely measured annually for the majority of patients. Patient records and information were anonymized and de-identified prior to analysis.
Study outcomes
The primary outcome in our analysis was incident high TC, defined as a TC > 6 mmol/L more than 90 days after ART initiation, in those who had a baseline TC < 6 mmol/L. Baseline TC was defined as a laboratory TC measurement taken up to 90 days prior to and 7 days after ART initiation. The 90-day cut-off was selected as the minimum time on ART to ensure that lipid profiles could be attributable to ART. We assessed the association of incident high TC with ART regimen at initiation, gender, age, BMI (kg/m 2 ), CD4 count (cells/lL), haemoglobin (g/dL), WHO clinical staging and tuberculosis status. The impact of ART regimen at initiation on incident high TC was analysed using an intention-to-treat approach and patients who switched ART during follow-up were not excluded from the analysis. In order to further evaluate the long-term impact on cholesterol, an additional analysis was performed looking at TC measurements subsequent to the first incident high TC measurement. Secondary outcomes included attrition (death and loss to follow-up) and clinical management of high incident TC and subsequent repeat TC. All-cause mortality was ascertained from patient records and the South African National Vital Registration System for patients with a valid South African national identification number [28] . Loss to follow-up was defined as ≥90 days late for the last scheduled visit.
Statistical analysis
Baseline demographic and clinical characteristics were summarized using descriptive statistics. We assessed data completeness of TC measurements by describing the proportion of patients who had TC measured on an annual basis among those still in care in addition to describing the corresponding rates of drop-outs because of death, loss to follow-up and transfer. We compared differences in baseline characteristics between those with and without follow-up TC measurements. A Cox proportional hazards regression model was used to identify clinical or demographic factors associated with incident high TC. Time to incident high TC was calculated from ART initiation to the earliest date of: (1) high TC, (2) death, (3) loss to follow-up, (4) transfer or (5) data set closure (5 April 2016). Time to death or loss to follow-up was calculated from the ART initiation date to either the date of death or the date of loss to follow-up, respectively, or the date of data set closure, whichever occurred first. Risk ratios were calculated comparing management styles for elevated TC and subsequent repeat TC outcomes.
Ethical approval
Ethical approval for the use of data was provided by the Human Research Ethics Committee (Medical) of the University of the Witwatersrand (M140201). The study protocol was reviewed by the Institutional Review Board of the University of Witwatersrand who approved the collection of the data without informed consent and the use of an anonymous analytical data set.
Results
Study participants and cholesterol monitoring
Of the 10 690 patients initiating treatment at the study site between April 2010 and April 2014, 7383 were ART na€ ıve, initiated a standard first-line ART regimen, and were at least 18 years of age ( Fig. 1 ). In these patients, TC was monitored annually after ART initiation for most patients who remained in care: 84 To estimate the incidence of high TC, we excluded 113 (2.1%) patients who had a high TC at ART initiation in addition to 1104 patients who did not have a follow-up TC measurement > 90 days post-ART initiation. Of the 1104 patients without follow-up measurements, almost half were lost to follow-up (44.4%; n = 490), 28.0% (n = 309) were transferred out and 26.4% died, at a median of 5 months on ART (IQR 3-8 months). Patients with no follow-up data were clinically worse off than those with follow-up data; they were more likely to have a BMI < 18 kg/m 2 , a lower baseline CD4 count, a WHO stage III/IV condition and haemoglobin < 10 g/dL, and were more likely to have had tuberculosis diagnosed at ART initiation (Table S1 ); they were also more likely to be male.
Of the 4091 patients with follow-up data, 60.7% were female, the median age at ART initiation was 38 (IQR 32-45) years and the median baseline CD4 count was 158 (IQR 76-231) cells/lL (Table 1) . Most patients (80.6%; n = 3296) were initiated on an ART regimen consisting of 3TC, TDF and EFV, with the remainder initiated on 3TC, d4T and EFV (11.5%; n = 469); 3TC, TDF and NVP (4.6%; n = 186); 3TC, ZDV and EFV (2.2%; n = 91); or other ART regimens (1.2%; n = 49). The median followup time from ART initiation to either last visit date or database closure was 4.0 years (IQR 3.0-4.8 years), during which patients had a median of 3 measurements for TC (IQR 2-5).
Patients who initiated a TDF-based regimen were younger, had slightly higher BMI and CD4 count at baseline, and were less likely to have low haemoglobin or be WHO stage III/IV (Table 1) , compared with those on a non-TDF-based regimen.
Incident high total cholesterol
Overall there were 595 incident cases of TC ≥ 6 mmol/L at any point after ART initiation, in 13 783 total personyears, corresponding to an incidence rate of 4.32 per 100 person-years (PY) [95% confidence interval (CI) 3.98-4.68 per 100 PY]. Of these, 496 (83.4%) had a repeat TC available at a median of 11.6 months (IQR 6.9-12.9 months) after their initial high TC, 61.7% (n = 306) of whom had a TC < 6 mmol/L.
There was no significant trend in incident high TC by year of ART initiation: 4. 
Clinical and demographic predictors of high TC
Factors associated with increased risk of incident high TC are shown in Table 2 . As expected, the single biggest risk factors for an elevated TC were age and BMI. Patients aged ≥ 40 years at the time of ART initiation were at almost three-fold increased risk of having a high TC after treatment initiation [hazard ratio (HR) 3.22; 95% CI 2.07-4.99], compared with patients aged < 30 years. Those who had a BMI 25-29.9 or ≥ 30.0 kg/m 2 were between 65 and 75% more likely to have a high TC compared with those who had a normal BMI (18-24.9 kg/m 2 ). Still, even after accounting for these two factors, drug regimens played a role. Most patients were initiated on TDF-based regimens (85.1%), with most of the remaining on d4T (12.1%) or ZDV (2.2%). Patients who were initiated on a non-TDF-based regimen, compared with those on a TDFbased regimen, had a 50% increased risk of having a high TC (HR 1.54; 95% CI 1.14-2.08). This association occurred early after ART initiation, as depicted in the Kaplan-Meier graph (Fig. 2) ; by 1 year post-ART, the probability of incident high TC was 4.8% and 8.8% for TDF-and non-TDF-based regimens, respectively (Fig. 2) . Patients initiating on non-TDF regimens were older (53.9% vs. 39.3% of patients on non-TDF-based and TDFbased regimens, respectively, were aged ≥40 years) but adjusting for other covariates, including age, did not affect the estimated impact of a non-TDF regimen on incident high TC. Although the estimates lacked precision, patients with baseline CD4 counts of < 50 and 50-99 cells/lL were, respectively, 55% and 40% more likely Values are n (%) unless otherwise stated. 3TC, lamivudine; d4T, stavudine; EFV, efavirenz; IQR, interquartile range; NVP, nevirapine; TB, tuberculosis; TC, total cholesterol; TDF, tenofovir; WHO, World Health Organization; ZDV, zidovudine. to have an incident high TC compared with those who initiated at a CD4 count ≥ 200 cells/lL.
Clinical management and outcomes among patients with elevated total cholesterol
Of the 595 patients with elevated TC on ART, 10 (1.7%) died and 34 (5.7%) were lost to follow-up at a median of 13.8 and 17.0 months after their incident high TC, respectively (Fig. 1) . Among the 496 patients with an initial elevated TC and a repeat TC measurement thereafter, rates of mortality for those with repeat TC < 6 and ≥ 6 mmol/L were 5.82 per 1000 PY (95% CI 1.89-13.58 per 1000 PY) and 7.08 per 1000 PY (95% CI 1.93-18.12 per 1000 PY), respectively. Rates of loss to follow-up in those with repeat TC measurements < 6 and ≥ 6 mmol/L were similar at 1.16 per 100 PY (95% CI 0.56-2.14 per 100 PY) and 1.24 per 100 PY (95% CI 0.50-2.55 per 100 PY), respectively. However, it should be noted that the number of deaths and losses to follow-up were extremely small in this subgroup. A third (36.5%) of patients with elevated TC were prescribed cholesterol-lowering drugs following their initial high TC, while the majority (59.3%) were likely to have received dietary counselling. A small proportion of patients had an ART regimen switch only (2.7%) or a combination of both cholesterol-lowering drugs and an ART switch (1.5%) (Fig. 3) . Along with repeat TC measurements during further follow-up, just over half of patients were prescribed cholesterol-lowering drugs: 50.1%, 57.3% and 59.8% of patients with incident high TC received cholesterol-lowering drugs after their first, second and third repeat TC measurements, respectively, each spaced at about 12 months apart (Fig. 3) . A majority of patients ultimately received cholesterol-lowering drugs (61.0%), while fewer had only an ART switch (4.7%) or a combination of an ART switch and cholesterol-lowering drugs (2.5%). Of the 31.8% (n = 189) who had no medical intervention at all, 82.5% only ever had one elevated TC measurement and about half of these never had a repeat measurement to assess TC further. Thirty-three of those with incident high TC had at least one repeat TC > 6 mmol/L, but reportedly did not receive any medical treatment for it.
Discussion
This study found increased rates of elevated TC in a South African adult population on ART and found that, consistent with previous reports [7, 9, 12, 13, [18] [19] [20] [21] [22] [23] [24] , TDF had a favourable impact on TC compared with other NRTIs. A strength of our study is that close to 95% of our patients were initiated on EFV, eliminating the possibility that the difference in TC levels associated with the NRTIs used (TDF vs. non-TDF) was a result of confounding by differing ART regimens. As expected, we found that older patients and patients with increased BMI were at an increased risk of high cholesterol, suggesting that such patients should be monitored closely and perhaps be prioritized for cholesterol-lowering drugs, which are effective at lowering cholesterol levels, while at the same time receiving lifestyle and diet counselling. As patients on chronic ART are followed over the long term, a concerted effort needs to be made to monitor those who have recurrent or persistently high TC.
While we were not able to assess the impact of a change in ART regimen in this cohort, other studies have shown that a switch to specific PIs, such as atazanavir, can improve the lipid profiles of those on ART; in addition to this, a change in diet could greatly benefit the patient in the long term [19] [20] [21] [22] [23] [24] . However, there does not seem to be a simple solution to this problem and treating dyslipidaemia in patients on ART requires a combination of interventions and close, regular monitoring to ensure the success of these interventions.
An important limitation of our study was the large number of patients who were excluded because of missing data. About a quarter of our study population were excluded because baseline TC was missing, while a further fifth did not have follow-up TC measurements; both of these were required to determine our primary outcome of high TC incidence. We determined that patients without follow-up outcome measurements were more likely to be less well, with lower BMI, making it possible that we overestimated the incidence of high TC. However, patients with missing follow-up measurements were also more likely to have been initiated on non-TDF regimens and/or to have a lower baseline CD4 count, both of which have been shown to increase a patient's risk of having incident high TC. Furthermore, we were limited to TC data only and did not have sufficient data on LDL-c and HDL-c to add to the analysis, which could have cast more light on the relationship between ART and changes in lipid profiles.
Our study contributes to the body of evidence of the impact of ART on TC, one of the key CVD risk factors. We have also highlighted the importance of regular, robust and systematic monitoring of patients on longterm ART, especially after the initial high TC has been diagnosed and treated to ensure patients reach and maintain lower TC levels. We found that about two-thirds of Fig. 3 Clinical management of elevated cholesterol amongst those with incident high total cholesterol, stratified by number of repeat measurements performed. ART, antiretroviral therapy; IQR, interquartile range; TC, total cholesterol. patients with elevated TC eventually received medical treatment after repeated elevated test results. For patients with an initial high TC, more frequent cholesterol monitoring is required, in order to allow earlier treatment of those who need it. Current South African ART guidelines do not call for regular TC monitoring in adults, but the risk of untreated high TC suggests that they should. For most patients on ART, annual ART monitoring visits are the only regular exposure many patients on ART have to health care. The opportunity to monitor noncommunicable disease risks should not be missed.
